Document is current

Article History

Received: 24 January 2024

Accepted: 1 August 2025

First Online: 1 October 2025

Declarations

:

: The present study was designed, conducted and reported in accordance with the ethical principles laid down in the Declaration of Helsinki, the Guidelines for Good Pharmacoepidemiology Practice of the International Society for Pharmacoepidemiology, the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines where applicable, the EU General Data Protection Regulation, and the local rules and regulations. In compliance with the latter, the final protocol of this Observational Study, including the final version of the Subject ICF, along with any amendments have been approved in writing by the Institutional Review Board of each participating hospital. National Ethics Committee (NEC) approval was waived based on local legislation. Informed consent was obtained from all individual participants included in the study except for deceased patients for whom a waiver of consent has been granted by the Institutional Review Board of each study site.

: Not applicable.

: Ippokratis Korantzis, Anna Koumarianou, Vassiliki Rapti, Adamantia Nikolaidi, Vasileios Barbounis, Athina Christopoulou, Dimitrios Mavroudis, Vassilios Georgoulias, Georgios Kesisis, and Alexandros Ardavanis have no relevant financial or non-financial interests to disclose; Eleni Timotheadou has received research funding and honoraria from Roche, AstraZeneca, Amgen, Genesis, Pfizer, GSK, MSD, Novartis; Christos Christodoulou declared financial or non-financial interest with Amgen, AstraZeneca, BMS, Genesis, Gilead, Lilly, Merck, MSD, Novartis, Pfizer, Roche; Dimitrios Tryfonopoulos has received honoraria from Roche, AstraZeneca, Genesis-pharma; Sofia Karageorgopoulou has received honoraria for satellite lectures/advisory boards and research compensation and/or conference registration fees and travel grants from Amgen, AstraZeneca, Gilead Sciences, Genesis Pharma, GlaxoSmithKline, MSD, Novartis, Pfizer, Roche, Teva; Ioannis Boukovinas has received honoraria from Roche, MSD, Bristol-Myers Squibb, Pfizer, Novartis, Merck, AstraZeneca, LEO Pharma, Servier, consulting or advisory role fees from Roche, Sanofi, AstraZeneca, Bristol-Myers Squibb, LEO Pharma, MSD, Novartis, Ipsen, Genesis Pharma, research funding from Roche, Novartis, Bristol-Myers Squibb, MSD, Regeneron, Boehringer Ingelheim, Lilly, Pfizer, and travel, accommodations, expenses support from MSD, Roche, Pfizer, Bristol-Myers Squibb; Flora Zagouri has received honoraria for lectures and has served in an advisory role for AstraZeneca, Daiichi, Eli- Lilly, Merck, Novartis, MSD, Pfizer, Genesis- Pharma and Roche; Konstantinos Papazisis has received honoraria and consultancy fees from MSD, Gilead, AstraZeneca, Novartis, Genesis, IPSEN, Eli Lilly, Roche and GSK, research funding from Roche, MSD, Novartis, Daiichi Sankyo, Eli Lilly, Nektar, AstraZeneca, BMS, Sanofi, Boehringer and EISAI; Evangelia Razis has received travel grants from BMS, Roche, Pfizer, Karyo, Gilead Sciences and Genesis Pharma. Furthermore, Dr Razis has received honoraria from Servier pharmaceuticals and research funding from Tesaro, IQvia, AstraZeneca, Exelixis, PPD Global and MSD. Dr Razis has served in consulting/advisory role for AstraZeneca; Emmanuel I Papadopoulos and Rozalia Michalea are employees of AstraZeneca Greece. The Study was designed collaboratively by the Sponsor and Investigators. The sponsor had no involvement in the collection, analysis, and interpretation of data. A Medical writing vendor was used and paid by the sponsor to compose the first draft of the manuscript which was reviewed and approved by all authors who unanimously made the decision to submit the manuscript for publication.